G
Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.94
-0.03 (-2.60%)
Market Cap: $622.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Geron Corporation (GERN) Valuation Multiples
Geron (GERN) trades at 2.9x sales and 2.8x book value. Its P/B of 2.8x is below its 5-year median of 4.8x. Its forward P/E is 48.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 48.3x |
| Price to sales | 2.9x |
| Price to book | 2.8x |
| PEG | N/A |
| FCF yield | -14.4% |
Historical Medians
Against its 10-year medians, its P/B is 17.6% below 3.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 2.8x | 4.8x | 3.4x |
Valuation History
Over the 6 of the 10 year ends shown that have a P/S, its P/S ranged from 30.0x in 2024 to 566.3x in 2019. 2024 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.32 | N/A | 3.9x |
| 2024 | $3.54 | 30.0x | 8.2x |
| 2023 | $2.11 | N/A | 5.1x |
| 2022 | $2.42 | N/A | 12.3x |
| 2021 | $1.22 | 288.9x | 3.2x |
| 2020 | $1.59 | N/A | 2.4x |
| 2019 | $1.36 | 566.3x | 2.0x |
| 2018 | $1.00 | 164.5x | 1.0x |
| 2017 | $1.80 | 269.1x | 2.8x |
| 2016 | $2.07 | 53.4x | 2.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GERN
What is GERN's forward P/E ratio?
Geron has a forward P/E ratio of 48.3x.
Is GERN stock overvalued?
GNG's valuation label for GERN is Undervalued.
What is GERN's price to sales ratio?
Geron has a price to sales ratio of 2.9x.
GERN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors